Preclinical activity of resazurin in acute myeloid leukaemia
British Journal of Haematology · 2025
DOI: 10.1111/bjh.19872 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Trung Quang Ha und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Oxazines, Leukemia, Myeloid, Acute, Xanthenes, Antineoplastic Agents. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Helse Vest, Kreftforeningen.
Abstract (Originalsprache)
Resazurin, a phenoxazine used in cell viability assays, acts in vitro as an anti‐leukaemic compound through the production of cellular reactive oxygen species (ROS) resulting in mitochondrial dysfunction and cell death. However, the in vivo tolerance and efficacy of resazurin in cancer are unknown. In this study, we investigated the in vitro and in vivo effects of resazurin in acute myeloid leukaemia (AML). Resazurininduced cell death in a dose‐dependent manner in AML cell lines and reduced proliferation and colony formation in ex vivo treated patient‐derived AML cells. Cells treated with a reduced dose of resazurin for 72 h acquired a more mature immunophenotype suggesting cell differentiation as a mechanism contributing to the anti‐leukaemic effect. In vivo optical imaging in healthy mice demonstrated a reduction of resazurin to resorufin within 30 min and non‐detectable after 2 h, supporting dosing twice daily as optimal. In subcutaneous and orthotopic models of MV4‐11 AML in NOD/SCID IL2rγ null mice, anti‐tumour effects and an increased survival were found at a dose level of 75 mg/kg twice daily without observed toxicity. Our results suggest that resazurin represents a novel experimental therapeutic for the treatment of AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
- Department of Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway.
- K.G. Jebsen Centre for Myeloid Blood Cancer, Department of Clinical Science, University of Bergen, Bergen, Norway.
- Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway.
- KinN Therapeutics AS, Bergen, Norway.
- Leukemia Research Group, Department of Clinical Science, University of Bergen, Bergen, Norway.
ORCID-Profile: Vibeke Andresen, Bjarte Skoe Erikstein, Stein-Erik Gullaksen, Håkon Reikvam, Emmet McCormack, Bjørn Tore Gjertsen
Förderung
- Helse Vest
- Kreftforeningen
Zitieren
APA
Ha, T. Q., Andresen, V., Erikstein, B. S., Popa, M., Gullaksen, S. E., Reikvam, H., McCormack, E., & Gjertsen, B. T. (2025). Preclinical activity of resazurin in acute myeloid leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.19872
Vancouver
Ha TQ, Andresen V, Erikstein BS, Popa M, Gullaksen SE, Reikvam H, et al. Preclinical activity of resazurin in acute myeloid leukaemia. British Journal of Haematology. 2025. doi:10.1111/bjh.19872
BibTeX
@article{Ha2025,
author = {Ha, Trung Quang and Andresen, Vibeke and Erikstein, Bjarte Skoe and Popa, Mihaela and Gullaksen, Stein-Erik and Reikvam, Håkon and McCormack, Emmet and Gjertsen, Bjørn Tore},
title = {Preclinical activity of resazurin in acute myeloid leukaemia},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.19872}
}
EUVIMED